Cohance ADC Play: Strong Growth Outlook

  Published 7 months ago

Broker cites Cohance’s strong ADC pipeline and growth levers, forecasting robust sales and EBITDA expansion.

  • Integrated ADC services and cross‑selling boost Cohance’s market position amidst easing specialty chemicals destocking pressures
  • Recovery expected by FY26, supporting projected 20% sales CAGR and 26% EBITDA CAGR through FY28
  • Cohance, formed from the Suven merger, offers global CRDMO capabilities targeting innovative pharmaceutical collaborations and growth

You might like these

Gold Dips Amid Dollar Strength & Trade Tensions

India PMI Shows Strong July Growth

Biocon Eyes Generic Wegovy Launch

India's Wheat Boom: Global Prices to Fall

Udaipur Air Terminal Electrical Contract Awarded

OneSource Closes USFDA Inspection Successfully

Honda Expands India Motorcycle Production

News that matters the most ⚡